Conclusion The discovery of GLP-1 agonists' potential in treating chronic kidney disease is an exciting development in medical research
K., Thomsen, M., Wortwein, G., & Fink-Jensen, A
Mr spectroscopy of the human brain with enhanced signal intensity at ultrashort echo times on a clinical platform at 3T and 7T
Instead, the Lira-AcGIP preparation demonstrated an enhanced glycemic control compared to Liraglutide, N-AcGIP, and the simple combination of Liraglutide and N-AcGIP (1745% reduction
According to a report from the WHO, in 2022, ~830 million people worldwide had diabetes, and over 95% of diabetes cases are type 2
This was inspired by prior GIP (glucose-dependent insulinotropic polypeptide) research, highlighting that besides GIP, other substances in the intestine also stimulate insulin secretion